Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of AVZO-021 in Advanced Solid Tumors
2024-517339-30-00Phase 2Authorised
- Sponsor
- Avenzo Therapeutics
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of ARTS-021 in Nonhematologic neoplasms (2 arms), sponsored by Avenzo Therapeutics. Planned start Mar 2025; status: authorised.
02
Drugs
ARTS-021
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-517339-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517339-30-00.